3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Neuroblastoma
20
Glioblastoma
4
Lung Neoplasms
3
Gliosarcoma
3
Glioma
3
Carcinoma, Non-Small-Cell Lung
3
Brain Neoplasms
3
Uterine Cervical Neoplasms
2
Small Cell Lung Carcinoma
2
Oligodendroglioma
2
Neoplasms
2
Leukemia, Myelomonocytic, Juvenile
2
Leukemia, Myeloid, Acute
2
Leukemia
2
Kidney Neoplasms
2
Central Nervous System Neoplasms
2
Astrocytoma
2
Wilms Tumor
1
Squamous Cell Carcinoma of Head and Neck
1
Skin Neoplasms
1
Rhabdoid Tumor
1
Recurrence
1
Pyloric Stenosis, Hypertrophic
1
Prostatic Neoplasms
1
Pinealoma
1
Penile Neoplasms
1
Neuroendocrine Tumors
1
Neuroectodermal Tumors, Primitive
1
Neoplasms, Second Primary
1
Neoplasms, Plasma Cell
1
Interventions
Cisplatin
7
Etoposide
6
Amifostine
6
Radiotherapy
5
Drug Therapy
5
Cyclophosphamide
5
apatinib
4
Methotrexate
4
Filgrastim
4
Cytarabine
4
sodium thiosulfate
3
Methylprednisolone
3
Carboplatin
3
pegfilgrastim
2
glucarpidase
2
etoposide phosphate
2
Voriconazole
2
Vincristine
2
Social Determinants of Health
2
Pyridoxine
2
Nivolumab
2
Gemcitabine
2
Doxorubicin
2
Docetaxel
2
Chemotherapy, Adjuvant
2
Capecitabine
2
trastuzumab deruxtecan
1
selinexor
1
sargramostim
1
sacituzumab govitecan
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Drug-Related Side Effects and Adverse Reactions
×
Isotretinoin
×
Clear all
NCT00002586
2020-05-15
13-Cis
University of Colorado, Denver
Phase 2
Completed
96 enrolled